Liraglutide Protects Kidneys From Cisplatin Damage by Blocking Ferroptosis Iron-Death Pathway

Liraglutide protected mouse kidneys from cisplatin-induced acute kidney injury by orchestrating ferroptosis defense mechanisms, adding renal protection to GLP-1 drug benefits.

RPEP-09732Animal studyPreliminary Evidence2025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
animal study
Evidence
Preliminary Evidence
Sample
N=N/A
Participants
Mice with cisplatin-induced acute kidney injury

What This Study Found

Liraglutide protected against cisplatin-induced acute kidney injury by orchestrating ferroptosis defense, including enhanced antioxidant defenses and reduced iron accumulation.

Key Numbers

Specific dose and kidney function measurements were analyzed but not detailed in available abstract.

How They Did This

Mouse model of cisplatin-induced acute kidney injury treated with liraglutide. Assessed kidney function, ferroptosis markers (iron, lipid peroxidation, GPX4), antioxidant defenses, and kidney histology.

Why This Research Matters

Cisplatin kidney damage limits cancer treatment. If liraglutide can protect kidneys during chemotherapy, cancer patients on GLP-1 drugs for diabetes or obesity may have a built-in advantage, and liraglutide could be specifically added as a kidney protector during chemo.

The Bigger Picture

GLP-1 drugs keep revealing organ-protective effects through unexpected mechanisms. Ferroptosis defense adds to the anti-inflammatory, antioxidant, and anti-apoptotic pathways already shown to mediate GLP-1 kidney protection. This multi-mechanism protection makes GLP-1 drugs increasingly important in nephrology.

What This Study Doesn't Tell Us

Mouse study. Cisplatin doses in mice may not match human chemotherapy protocols. The interaction between liraglutide and cisplatin anticancer efficacy needs evaluation — kidney protection must not compromise cancer treatment.

Questions This Raises

  • ?Does liraglutide protect kidneys without reducing cisplatin anticancer efficacy?
  • ?Should cancer patients on GLP-1 drugs continue them during cisplatin chemotherapy for kidney protection?
  • ?Could liraglutide or other GLP-1 drugs become standard nephroprotectants during chemotherapy?

Trust & Context

Key Stat:
Ferroptosis blocked Liraglutide activated iron-death defense mechanisms to protect kidneys during cisplatin chemotherapy in mice
Evidence Grade:
Preliminary evidence: well-designed mouse study with clear ferroptosis mechanism identification. No human chemotherapy data.
Study Age:
Published in 2025. Reveals a novel mechanism (ferroptosis defense) for GLP-1 kidney protection.
Original Title:
Liraglutide orchestrates ferroptosis defense against murine cisplatin acute kidney injury: NRF2 activation via both KEAP1-dependent and -independent mechanisms is essential for SLC7A11/GPX4 renoprotection.
Published In:
Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS), 92, 127755 (2025)
Database ID:
RPEP-09732

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

What is ferroptosis?

Ferroptosis is a form of cell death caused by iron-dependent damage to cell membranes. It is different from the more familiar apoptosis. In cisplatin kidney damage, ferroptosis is a major mechanism of cell death. Liraglutide appears to block this process.

Could GLP-1 drugs protect kidneys during chemotherapy?

This mouse study suggests yes — liraglutide protected kidneys from cisplatin damage by blocking ferroptosis. Cancer patients already taking GLP-1 drugs may have some built-in kidney protection, but clinical studies are needed to confirm this and ensure it does not affect cancer treatment.

Read More on RethinkPeptides

Cite This Study

RPEP-09732·https://rethinkpeptides.com/research/RPEP-09732

APA

Abdel Razek, Nermeen S; Nassar, Noha N; Sayed, Rabab H; El-Sahar, Ayman E; Abdallah, Dalaal M. (2025). Liraglutide orchestrates ferroptosis defense against murine cisplatin acute kidney injury: NRF2 activation via both KEAP1-dependent and -independent mechanisms is essential for SLC7A11/GPX4 renoprotection.. Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS), 92, 127755. https://doi.org/10.1016/j.jtemb.2025.127755

MLA

Abdel Razek, Nermeen S, et al. "Liraglutide orchestrates ferroptosis defense against murine cisplatin acute kidney injury: NRF2 activation via both KEAP1-dependent and -independent mechanisms is essential for SLC7A11/GPX4 renoprotection.." Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS), 2025. https://doi.org/10.1016/j.jtemb.2025.127755

RethinkPeptides

RethinkPeptides Research Database. "Liraglutide orchestrates ferroptosis defense against murine ..." RPEP-09732. Retrieved from https://rethinkpeptides.com/research/abdel-2025-liraglutide-orchestrates-ferroptosis-defense

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.